GlaxoSmithKline plc (GSK) Shares Sold by Nicholas Hoffman & Company LLC.

Nicholas Hoffman & Company LLC. trimmed its stake in GlaxoSmithKline plc (NYSE:GSK) by 35.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,174 shares of the pharmaceutical company’s stock after selling 11,498 shares during the period. Nicholas Hoffman & Company LLC.’s holdings in GlaxoSmithKline were worth $751,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Fisher Asset Management LLC grew its position in GlaxoSmithKline by 2.3% in the 3rd quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock worth $520,827,000 after purchasing an additional 293,866 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its position in shares of GlaxoSmithKline by 7.3% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock valued at $341,727,000 after acquiring an additional 569,600 shares in the last quarter. NWQ Investment Management Company LLC boosted its position in shares of GlaxoSmithKline by 9.4% during the 3rd quarter. NWQ Investment Management Company LLC now owns 2,728,458 shares of the pharmaceutical company’s stock valued at $110,775,000 after acquiring an additional 233,689 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of GlaxoSmithKline by 7.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,855,142 shares of the pharmaceutical company’s stock valued at $75,028,000 after acquiring an additional 122,634 shares in the last quarter. Finally, Hamlin Capital Management LLC boosted its position in shares of GlaxoSmithKline by 0.4% during the 3rd quarter. Hamlin Capital Management LLC now owns 1,772,997 shares of the pharmaceutical company’s stock valued at $71,984,000 after acquiring an additional 7,882 shares in the last quarter. Institutional investors own 9.52% of the company’s stock.

Several brokerages have recently weighed in on GSK. Zacks Investment Research lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. TheStreet lowered shares of GlaxoSmithKline from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. Kepler Capital Markets upgraded shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Friday, February 9th. Cowen reiterated a “hold” rating and set a $40.00 target price on shares of GlaxoSmithKline in a research report on Thursday. Finally, Investec lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $38.97.

GlaxoSmithKline plc (NYSE:GSK) opened at $37.70 on Friday. GlaxoSmithKline plc has a 1-year low of $34.52 and a 1-year high of $44.53. The stock has a market cap of $91,790.00, a PE ratio of 43.33, a P/E/G ratio of 2.37 and a beta of 0.98. The company has a current ratio of 0.60, a quick ratio of 0.39 and a debt-to-equity ratio of 4.09.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The firm had revenue of $10.14 billion during the quarter, compared to the consensus estimate of $9.89 billion. equities analysts predict that GlaxoSmithKline plc will post 2.85 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 12th. Investors of record on Friday, February 23rd will be issued a dividend of $0.633 per share. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 annualized dividend and a yield of 6.72%. The ex-dividend date of this dividend is Thursday, February 22nd. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 234.48%.

TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/18/glaxosmithkline-plc-gsk-shares-sold-by-nicholas-hoffman-company-llc.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply